Hepion Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OQB
Hepion Pharmaceuticals has issued its 2026 proxy statement detailing director elections, auditor ratification, and a significant expansion of its equity incentive plan.
OQB
DEF: Hepion Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split and Director Elections
Hepion Pharmaceuticals is holding its annual meeting on June 12, 2025, seeking stockholder approval for key proposals including a reverse stock split and the election of directors.
OQB
Hepion Pharmaceuticals is asking stockholders to vote on key proposals at its annual meeting, including a reverse stock split and approval for the issuance of shares related to warrant exercises.
OQB
Pharma Two B presented positive integrated safety and efficacy data for its Parkinson's disease drug, P2B001, and is progressing towards a merger with Hepion Pharmaceuticals.
OQB
Hepion Pharmaceuticals is urging its shareholders to vote in favor of a proposed merger with Pharma Two B, citing financial challenges and the potential upside of Pharma Two B's Parkinson's disease treatment.